Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nektar Therapeutics - Common Stock (NQ:NKTR)

24.39 -0.19 (-0.79%)
Streaming Delayed Price Updated: 1:24 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Nektar Therapeutics - Common Stock

< Previous 1 2 3 4 5 6 Next >
3 Bullish Biotech Stocks With Explosive Growth Trends
These small-cap biotech stocks offer high-reward potential with bullish momentum and key catalysts ahead in urology, autoimmune, and gene editing therapies 
Via MarketBeat
Why Nektar Therapeutics Stock Dived by 3% Today
Via The Motley Fool
US Stock Futures Slip After Two Days Of Record Advances: 'FOMO Could Add Another 5%-10%...,' Says Expert
U.S. futures slipped on Tuesday after two days of record-setting advances. Futures of major benchmark indices were trading lower. 
Via Benzinga
MSC Industrial Direct, Constellation Brands And 3 Stocks To Watch Heading Into Tuesday
 
Via Benzinga
Earnings Scheduled For May 8, 2025
 
Via Benzinga
Nektar Therapeutics's Earnings: A Preview
 
Via Benzinga
Biotech Catalyst Alert: NKTR, CDTX & WGS Rallying With Big Gains
With major rallies and analyst backing, Nektar, Cidara, and GeneDx are drawing interest; will these biopharma firms maintain their growth trajectories? 
Via MarketBeat
Nektar Jumps 157% on Drug Trial Data—Can It Go Even Higher?
Nektar Therapeutics soared 157% after Rezpeg succeeded in a Phase 2b eczema trial. Analysts forecast huge upside—here’s why there could be more gains ahead. 
Via MarketBeat
Nektar Nails Phase 2b Eczema Trial: BTIG Calls It A ‘Pound the Table BUY’, Wainwright Sees $120 Upside
The data showed strong efficacy across multiple endpoints and consistent safety, reinforcing confidence in rezpegaldesleukin’s potential as a differentiated treatment for atopic dermatitis. 
Via Stocktwits
Why Nektar Therapeutics Stock Was Red-Hot Today
Via The Motley Fool
Why Is Nektar Therapeutics Stock Trading Higher On Wednesday?
Nektar's rezpegaldesleukin met key efficacy targets in a mid-stage eczema study, though analysts flagged safety and differentiation concerns. 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
AeroVironment Posts Better-Than-Expected Earnings, Joins QuantumScape, Bumble, BlackBerry And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Curious to know what's happening on the US markets in the middle of the day on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Nektar Therapeutics Announces Positive Data From Eczema Drug In Mid-stage Trial: Stock More Than Doubles But Retail Sees It Rising Further
Nektar Therapeutics said its mid-stage trial showed that patients who received Rezpegaldesleukin demonstrated improvement in eczema area and severity score compared to placebo at week 16. 
Via Stocktwits
Topics Economy Government
Crude Oil Falls Sharply; US Current Account Deficit Widens In Q1
 
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Looking for insights into the US markets in the middle of the day on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
Which stocks are gapping on Tuesday?
The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. 
Via Chartmill
Nasdaq Surges 1%; TD Synnex Posts Upbeat Earnings
 
Via Benzinga
Nektar Therapeutics Shares Double On Promising Eczema Drug Data
Nektar reported positive Phase 2b trial data for rezpegaldesleukin in atopic dermatitis, showing strong efficacy and a consistent safety profile. 
Via Benzinga
Nektar Therapeutics Launches By Triple Digits On Eczema Grand Slam
The company's experimental eczema drug met all the primary and secondary goals in a midstage study. 
Via Investor's Business Daily
Tuesday's pre-market session: top gainers and losers
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Why Nektar Therapeutics Shares Are Trading Higher By Over 30%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
US Stocks Likely To Open Higher After Trump Announces Iran-Israel Ceasefire: FedEx, TD Synnex In Focus Ahead Of Earnings
U.S. futures were trading higher on Tuesday after a positive day of trade on Monday. Futures of major benchmark indices were trading higher. 
Via Benzinga
Topics Government
Nektar Therapeutics Stock Rallies Sharply After-Hours With Major Skin Drug Results Just Hours Away
Rezpegaldesleukin is being studied not only in atopic dermatitis but also in alopecia areata, with topline data from the second trial expected in December. 
Via Stocktwits
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
Top movers in Monday's after hours session
After the closing bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session. 
Via Chartmill
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.